Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line MK-1454 intratumoral injection plus pembrolizumab versus pembrolizumab alone in recurrent/metastatic head and neck squamous cell carcinoma
MOH_2019-12-29_008581Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing MK-1454 + pembrolizumab with Pembrolizumab (2 arms). Started Dec 2019; status: completed.
02
Drugs
Ulevostinagpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2019-12-29_008581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-29_008581.